Immunotherapy and Immune Responses

This paper shows that cationic liposome-formulated TLR7/8 agonist enhances fentanyl vaccine efficacy by improving immune activation and protecting against fentanyl-induced toxicity in rats.

The paper identifies IFN-induced activation of dendritic cells and monocytes after yellow fever vaccination as correlated with early protective antibody responses.

This study identifies immunoregulatory dendritic cells in brain tumor draining lymph nodes and shows OX40 can target them to improve immunotherapy.

This study investigates how viral infection affects DC progenitor development, finding that glucocorticoids suppress pDC generation by altering transcriptional and epigenetic programs.

This paper develops an in vitro protocol to generate human dendritic cells from iPSC with a feeder-free expansion step, resulting in DC1-like cells that show functional characteristics similar to monocyte-derived DCs.

This study examines the early spatiotemporal immune response to Ad26 vaccination in mice, showing rapid innate activation in tissues and blood that correlates with later memory CD8+ T cell responses.

The paper identifies RORγt-expressing dendritic cells as a distinct APC lineage conserved across tissues and species, with functions beyond promoting tolerance.

This study develops a neoantigen vaccine using SARS-CoV-2 B cell epitopes to enhance CD4/CD8 T cell immunity through B cell antigen presentation, showing improved efficacy in multiple cancer models.

This paper introduces OncoMimics, a peptide-based immunotherapy using molecular mimicry between commensal bacterial and tumor antigens to induce cross-reactive T cell responses, showing early clinical success in glioblastoma.

The paper shows that genomic instability in MSI CRCs generates cytosolic DNA that enhances STING activation and anti-tumor immunity via dendritic cells, suggesting improved DNA-based therapies for CIN CRCs.

This study shows that second-generation LNPs (Lipidots(R)) enhance antitumor immunity by remodeling the tumor microenvironment and synergizing with PD-1/PD-L1 blockade to improve therapeutic outcomes in cold tumors.

The paper identifies a novel CD103- cDC2 subset in rats that exhibits enhanced immunogenicity compared to CD103+ cDC2s and shares markers with mouse and human cDC2 subsets.

This study shows spermidine suppresses dendritic cell activation through eIF5A hypusination and metabolic adaptation, reducing their ability to interact with T cells.

This study shows that intracellular C3d enhances immune surveillance by inducing T cell responses against malignant plasma cells while sparing normal cells in a murine model of multiple myeloma.

The paper shows that glutamine availability affects the number of type 1 conventional dendritic cells (cDC1s) in tumor microenvironments, which impacts anti-tumor immune responses.

This study compares the immune response in non-human primates between alum and SMNP adjuvants, finding SMNP induces stronger humoral responses and enhanced lymph node activation.

This study shows adjuvants like MPLA and CpG reduce high-stability peptide presentation on APCs, shifting T-cell immunodominant epitope responses.

This paper conjugates a TLR7 agonist to a peptide hydrogel to create a vaccine adjuvant that produces antibody titers similar to alum and a more balanced Th1/Th2 immune response.

This study shows that administering 4-1BB costimulatory antibodies after 96 hours post-mRNA vaccination enhances CD8 T cell responses and protection against breakthrough infections.

This study shows that combining radiotherapy with CpG, a TLR9 agonist, enhances tumor response in a mouse sarcoma model by boosting CD8 T cell activity.

The paper develops a biomimetic nanoparticle-ligand platform to stimulate immune cells by mimicking antigen-presenting cell microvilli structures.

This study develops glycan-costumed virus-like particles that activate dendritic cells and induce type 1 anti-tumor immunity in a murine model.

This study shows that lamin A/C is essential for dendritic cell function in antiviral immunity by modulating epigenetic and transcriptional processes.

The paper investigates how monocyte differentiation in adult skin leads to Langerhans cell identity through intrinsic and extrinsic factors.

This study shows that mucosal rAd5 vaccines targeting HPV16 E6 and E7 proteins reduce tumor volume and improve survival in a mouse model of HPV-induced cancer.

This paper develops SAPCon, a polymer-drug conjugate that activates the STING pathway in tumors, enhancing immunotherapy efficacy by promoting an immunogenic microenvironment and improving tumor growth inhibition.

This study shows that delivering IRF8 via retroviral vector reprograms myeloid cells in glioblastoma, enhancing anti-tumor immunity and reducing immunosuppression.

This study develops CD45-targeted immunocytokines that localize to immune cells in tumors and lymph nodes, eradicating both treated and distant tumors in mouse models.

This study reprograms tumor cells in vivo to function as dendritic cells, leading to tumor regression and long-term immunity in mouse models.